infectious-diseases-2018-posters-abstracts

32 / 35

Infectious Diseases 2018 Journal of Prevention and Infection Control
ISSN: 2471-9668 Page 71
June 07-08, 2018
London, UK
8th Edition of International Conference on
Infectious Diseases
Background: Acute bacterial skin and skin structure (ABSSSI)
infections can cause a significant amount of morbidity and
mortality in hospitalized patients and outpatients as well.
Emerging resistance of gram-positive pathogens to different
drugs has narrowed down our options for treating skin infections.
Newer antimicrobials such as delafloxacin might prove to be
a useful alternative to treat skin infections caused by resistant
gram-positive pathogens.
Objective: The objective of this review is to assess all the available
evidence on delafloxacin in literature and compare its efficacy
with drugs routinely used to treat skin infections.
Methodology: An extensive literature search was conducted
using different databases. By using PubMed, EMBASE and
Cochrane central register of controlled trials 86 abstracts were
screened for eligibility. A total of six studies were finally included
in the narrative review and meta-analysis. The primary outcome
in this review was to assess the microbiological cure at the end of
the follow up period. Secondary outcome was clinical response
and absence of the signs and symptoms at the end of the follow
up period.
Results: A total of 86 abstracts were screened for review, out of
the 86 abstracts, 25 studies were further screened for eligibility,
and only six studies were finally included in the narrative review
and meta-analysis. By using RevMan software risk ratio (RR)
random effects model was used with 95% confidence interval.
The pooled efficacy of delafloxacin was at 80% 95 CI 1.01 (0.97,
1.06) =0.51. No statistically significant difference was found
between intravenous (IV delafloxacin) and comparator drugs.
Conclusion: Despite having a pooled cure rate of 80%, the efficacy
of delafloxacin was found to be non-inferior to tigecycline and
linezolid. Pooled cure rate and efficacy of delafloxacin was
also found to be superior to vancomycin. Therefore, it can be
ascertained that delafloxacin might prove as a useful alternative
for treating resistant gram-positive infections. However, more
high quality randomized controlled trials need to be conducted in
future in order to develop clinical guidelines.
Systematic review and meta-analysis, on the efficacy of
cefixime for treating gonococcal infections
Syed Bilal Tanvir, Syed Saad Bin Qasim and Mariam Kassir
Dar Al Uloom University, Saudi Arabia
J Prev Infect Cntrol 2018, Volume 4
DOI: 10.21767/2471-8084-C1-003